메뉴 건너뛰기




Volumn 14, Issue 5, 2012, Pages 649-657

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan

Author keywords

Anti angiogenic treatment; FDG PET; Prognosis; Recurrent high grade glioma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; ENZASTAURIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

EID: 84860370272     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos012     Document Type: Article
Times cited : (64)

References (51)
  • 1
    • 34547122001 scopus 로고    scopus 로고
    • The 2007 WHO classification of tumours of the central nervous system
    • Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
    • (2007) Acta Neuropathol. , vol.114 , pp. 97-109
    • Louis, D.N.1    Ohgaki, H.2    Wiestler, O.D.3
  • 3
    • 37449003812 scopus 로고    scopus 로고
    • Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    • Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
    • (2008) Lancet Oncol , vol.9 , pp. 29-38
    • Gorlia, T.1    Van Den Bent, M.J.2    Hegi, M.E.3
  • 5
    • 0032767387 scopus 로고    scopus 로고
    • Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
    • Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
    • (1999) J Clin Oncol , vol.17 , pp. 2572-2578
    • Wong, E.T.1    Hess, K.R.2    Gleason, M.J.3
  • 6
    • 34447285771 scopus 로고    scopus 로고
    • Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase i and II clinical trials
    • Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25:2601-2606.
    • (2007) J Clin Oncol , vol.25 , pp. 2601-2606
    • Carson, K.A.1    Grossman, S.A.2    Fisher, J.D.3    Shaw, E.G.4
  • 7
    • 38749146312 scopus 로고    scopus 로고
    • Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide
    • Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 2007;37:897-906.
    • (2007) Jpn J Clin Oncol , vol.37 , pp. 897-906
    • Nagane, M.1    Kobayashi, K.2    Ohnishi, A.3    Shimizu, S.4    Shiokawa, Y.5
  • 8
    • 32944469010 scopus 로고    scopus 로고
    • Changing paradigms-an update on the multidisciplinary management of malignant glioma
    • European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups National Cancer Institute of Canada Clinical Trials Group.
    • Stupp R, Hegi ME, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180.
    • (2006) Oncologist , vol.11 , pp. 165-180
    • Stupp, R.1    Hegi, M.E.2    Van Den Bent, M.J.3
  • 9
    • 0043236350 scopus 로고    scopus 로고
    • Summary version of the Standards Options and Recommendations for the management of adult patients with intracranial glioma 2002)
    • FNCLCC; Neuro-oncology Group of the Fédé ration Nationale des Centres de Lutte Contre le Cancer; Association of French-speaking Neuro-oncologists
    • Frappaz D, Chinot O, Bataillard A, et al. FNCLCC; Neuro-oncology Group of the Fédé ration Nationale des Centres de Lutte Contre le Cancer; Association of French-speaking Neuro-oncologists. Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer. 2003;89(Suppl.):73-83.
    • (2003) Br J Cancer. , vol.89 , Issue.SUPPL. , pp. 73-83
    • Frappaz, D.1    Chinot, O.2    Bataillard, A.3
  • 10
    • 70350461699 scopus 로고    scopus 로고
    • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
    • Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
    • (2009) J Clin Oncol , vol.27 , pp. 4733-4740
    • Friedman, H.S.1    Prados, M.D.2    Wen, P.Y.3
  • 11
    • 78449274656 scopus 로고    scopus 로고
    • A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    • Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116: 5297-5305.
    • (2010) Cancer. , vol.116 , pp. 5297-5305
    • Raizer, J.J.1    Grimm, S.2    Chamberlain, M.C.3
  • 12
    • 33947191055 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    • Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
    • (2007) Clin Cancer Res , vol.13 , pp. 1253-1259
    • Vredenburgh, J.J.1    Desjardins, A.2    Je, H.Ii.3
  • 13
    • 67649410669 scopus 로고    scopus 로고
    • Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    • Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009;72:1601-1606.
    • (2009) Neurology , vol.72 , pp. 1601-1606
    • Taillibert, S.1    Vincent, L.A.2    Granger, B.3
  • 14
    • 75649124562 scopus 로고    scopus 로고
    • Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    • Chamberlain MC. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2010;74:181.
    • (2010) Neurology. , vol.74 , pp. 181
    • Chamberlain, M.C.1
  • 15
    • 80755159087 scopus 로고    scopus 로고
    • A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
    • Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13:1143-1150.
    • (2011) Neuro Oncol. , vol.13 , pp. 1143-1150
    • Kreisl, T.N.1    Zhang, W.2    Odia, Y.3
  • 17
    • 0028129321 scopus 로고
    • Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery
    • Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery. 1994;35: 378-388.
    • (1994) Neurosurgery , vol.35 , pp. 378-388
    • Rostomily, R.C.1    Spence, A.M.2    Duong, D.3    McCormick, K.4    Bland, M.5    Berger, M.S.6
  • 18
    • 0031016159 scopus 로고    scopus 로고
    • 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma
    • Barker FG, 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer. 1997;79:115-126.
    • (1997) Cancer , vol.79 , pp. 115-126
    • Fg, B.Ii.1    Chang, S.M.2    Valk, P.E.3    Pounds, T.R.4    Prados, M.D.5
  • 19
    • 36048955738 scopus 로고    scopus 로고
    • Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study
    • Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25: 4714-4721.
    • (2007) J Clin Oncol , vol.25 , pp. 4714-4721
    • Chen, W.1    Delaloye, S.2    Silverman, D.H.3
  • 21
    • 79958148395 scopus 로고    scopus 로고
    • O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma
    • Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L- tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856-864.
    • (2011) J Nucl Med. , vol.52 , pp. 856-864
    • Hutterer, M.1    Nowosielski, M.2    Putzer, D.3
  • 23
    • 12444279265 scopus 로고
    • On the origin of cancer cells
    • Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
    • (1956) Science , vol.123 , pp. 309-314
    • Warburg, O.1
  • 25
    • 0020377044 scopus 로고
    • Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography
    • Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
    • (1982) Neurology , vol.32 , pp. 1323-1329
    • Di Chiro, G.1    Delapaz, R.L.2    Brooks, R.A.3
  • 26
    • 84864329014 scopus 로고    scopus 로고
    • Independant prognostic value of pre-treatment 18-FDG-PET in high grade gliomas
    • [published online ahead of print December 15 2011]. doi:10.1007/s11060- 011-0771-6
    • Colavolpe C, Metellus P, Mancini J, et al. Independant prognostic value of pre-treatment 18-FDG-PET in high grade gliomas. J Neurooncol [published online ahead of print December 15, 2011]. doi:10.1007/s11060-011-0771-6.
    • J Neurooncol
    • Colavolpe, C.1    Metellus, P.2    Mancini, J.3
  • 27
    • 0021798805 scopus 로고
    • Prediction of survival in glioma patients by means of positron emission tomography
    • Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816-822.
    • (1985) J Neurosurg , vol.62 , pp. 816-822
    • Patronas, N.J.1    Di Chiro, G.2    Kufta, C.3
  • 28
    • 0141794250 scopus 로고    scopus 로고
    • Prediction of pathology and survival by FDG PET in gliomas
    • Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
    • (2003) J Neurooncol , vol.64 , pp. 227-237
    • Padma, M.V.1    Said, S.2    Jacobs, M.3
  • 29
    • 0031968208 scopus 로고    scopus 로고
    • Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine
    • Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-785.
    • (1998) J Nucl Med , vol.39 , pp. 778-785
    • Kaschten, B.1    Stevenaert, A.2    Sadzot, B.3
  • 30
    • 0027313527 scopus 로고
    • FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma
    • Hö lzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr. 1993;17:681-687.
    • (1993) J Comput Assist Tomogr , vol.17 , pp. 681-687
    • Hölzer, T.1    Herholz, K.2    Jeske, J.3    Heiss, W.D.4
  • 31
    • 50649095167 scopus 로고    scopus 로고
    • FDG-PET to predict different patterns of progression in multicentric glioblastoma: A case report
    • Colavolpe C, Guedj E, Metellus P, et al. FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. J Neurooncol. 2008;90:47-51.
    • (2008) J Neurooncol , vol.90 , pp. 47-51
    • Colavolpe, C.1    Guedj, E.2    Metellus, P.3
  • 32
    • 0036554829 scopus 로고    scopus 로고
    • 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: Correlation with outcome
    • Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res. 2002;8:971-979.
    • (2002) Clin Cancer Res , vol.8 , pp. 971-979
    • Spence, A.M.1    Muzi, M.2    Graham, M.M.3
  • 33
    • 33645969631 scopus 로고    scopus 로고
    • Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies
    • Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418.
    • (2006) J Nucl Med , vol.47 , pp. 410-418
    • Cher, L.M.1    Murone, C.2    Lawrentschuk, N.3
  • 34
    • 33645991547 scopus 로고    scopus 로고
    • Microvessel density: Correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas
    • Guo J, Higashi K, Ueda Y, et al. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med. 2006;47:419-425.
    • (2006) J Nucl Med , vol.47 , pp. 419-425
    • Guo, J.1    Higashi, K.2    Ueda, Y.3
  • 35
    • 33750351328 scopus 로고    scopus 로고
    • European Association of Nuclear Medicine (EANM). EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues
    • Vander Borght T, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine (EANM). EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33:1374-1380.
    • (2006) Eur J Nucl Med Mol Imaging , vol.33 , pp. 1374-1380
    • Vander Borght, T.1    Asenbaum, S.2    Bartenstein, P.3
  • 36
    • 77951625266 scopus 로고    scopus 로고
    • Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group
    • Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72.
    • (2010) J Clin Oncol. , vol.28 , Issue.11 , pp. 1963-72
    • Wen, P.Y.1    MacDonald, D.R.2    Reardon, D.A.3
  • 37
    • 0022885139 scopus 로고
    • Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
    • Hamacher K, Coenen HH, Stö cklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
    • (1986) J Nucl Med , vol.27 , pp. 235-238
    • Hamacher, K.1    Coenen, H.H.2    Stöcklin, G.3
  • 39
    • 33744540372 scopus 로고    scopus 로고
    • Optimization of semiquantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas
    • Borbé ly K, Nyá ry I, Tó th M, Ericson K, Gulyá s B. Optimization of semiquantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci. 2006;246:85-94.
    • (2006) J Neurol Sci , vol.246 , pp. 85-94
    • Borbély, K.1    Nyáry, I.2    Tóth, M.3    Ericson, K.4    Gulyás, B.5
  • 40
    • 3042730538 scopus 로고    scopus 로고
    • High and low grade oligodendrogliomas (ODG): Correlation of amino-acid and glucose uptakes using PET and histological classifications
    • Giammarile F, Cinotti LE, Jouvet A, et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol. 2004;68:263-274.
    • (2004) J Neurooncol , vol.68 , pp. 263-274
    • Giammarile, F.1    Cinotti, L.E.2    Jouvet, A.3
  • 41
    • 0035111816 scopus 로고    scopus 로고
    • Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses
    • Meyer PT, Schreckenberger M, Spetzger U, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med. 2001;28:165-174.
    • (2001) Eur J Nucl Med , vol.28 , pp. 165-174
    • Meyer, P.T.1    Schreckenberger, M.2    Spetzger, U.3
  • 42
    • 0025075721 scopus 로고
    • Over-expression of facilitative glucose transporter genes in human cancer
    • Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
    • (1990) Biochem Biophys Res Commun , vol.170 , pp. 223-230
    • Yamamoto, T.1    Seino, Y.2    Fukumoto, H.3
  • 44
    • 0001644841 scopus 로고
    • Oxygen consumption and anaerobic glycolysis of human malignant and normal tissue
    • Macbeth RAL, Bekesi JG. Oxygen Consumption and Anaerobic Glycolysis of Human Malignant and Normal Tissue. Cancer Res. 1962;22:244-248.
    • (1962) Cancer Res , vol.22 , pp. 244-248
    • MacBeth, R.A.L.1    Bekesi, J.G.2
  • 45
    • 12444257678 scopus 로고    scopus 로고
    • Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value
    • Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51.
    • (2005) Eur J Nucl Med Mol Imaging , vol.32 , pp. 39-51
    • Van Laere, K.1    Ceyssens, S.2    Van Calenbergh, F.3
  • 46
    • 23044460494 scopus 로고    scopus 로고
    • Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG
    • Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-952.
    • (2005) J Nucl Med , vol.46 , pp. 945-952
    • Chen, W.1    Cloughesy, T.2    Kamdar, N.3
  • 48
    • 33748327010 scopus 로고    scopus 로고
    • Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy
    • Charnley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66: 331-338.
    • (2006) Int J Radiat Oncol Biol Phys , vol.66 , pp. 331-338
    • Charnley, N.1    West, C.M.2    Barnett, C.M.3
  • 49
    • 59949083263 scopus 로고    scopus 로고
    • Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    • Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27: 740-745.
    • (2009) J Clin Oncol , vol.27 , pp. 740-745
    • Kreisl, T.N.1    Kim, L.2    Moore, K.3
  • 50
    • 38549145873 scopus 로고    scopus 로고
    • 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
    • Funaioli C, Pinto C, Di Fabio F, et al. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori. 2007;93:611-615.
    • (2007) Tumori , vol.93 , pp. 611-615
    • Funaioli, C.1    Pinto, C.2    Di Fabio, F.3
  • 51
    • 33646675851 scopus 로고    scopus 로고
    • MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
    • Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260.
    • (2006) Neurology , vol.66 , pp. 1258-1260
    • Pope, W.B.1    Lai, A.2    Nghiemphu, P.3    Mischel, P.4    Cloughesy, T.F.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.